deltatrials
Completed PHASE2 INTERVENTIONAL NCT00080080

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Phase 2 Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Sponsor: Point Therapeutics

Conditions Lung Cancer
Interventions Docetaxel talabostat (PT-100) tablets
Updated 5 times since 2017 Last updated: Jun 7, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lung Cancer, this trial is completed. The trial is conducted by Point Therapeutics and has accumulated 5 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Point Therapeutics
Data source: Point Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations